# X4 Pharmaceuticals

**Canonical:** https://apis.io/providers/x4-pharmaceuticals/  
**Website:** https://www.x4pharma.com/  
**APIs profiled:** 0

X4 Pharmaceuticals develops and commercializes innovative therapies for rare immune system diseases. It has received U.S. approval for mavorixafor (XOLREMDI®) and is advancing it in a global Phase 3 trial. Headquartered in Boston, Massachusetts, X4 is publicly traded on Nasdaq under the symbol XFOR. The company focuses on patients with unmet needs, delivering progress through its Rare Resolve program.

## Kin Score — 12.5 / 100 (emerging)

Scored 2026-10-31 under rubric 0.25.0.

| Facet | Score |
|---|---|
| Discoverability | 44.6 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 9.5 |
| Access Clarity | 28.9 |

Regulatory layer — **Health**: 14.8 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## Security (1)

- **X4 Pharmaceuticals Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotechnology, Pharmaceuticals, Rare Diseases, Clinical Trials

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/x4-pharmaceuticals/). Scores are computed from the provider's own public artifacts under a published rubric.